1. New Pathways in Lipid Care

2. Treatment Gaps in Patients at High Risk for ASCVD and FH

3. Evidence-Based Statin Use in Patients With LDL-C > 190 mg/dL in the PINNACLE Registry (n = 49,447,241 Practices)

4. ODYSSEY OUTCOMES vs FOURIER LLTs

5. Comparison of Lipid Guidelines

6. Monitoring Therapeutic Response and Adherence to Statin Therapy ACC/AHA 2013 Lipid Guidelines

7. Variability in LDL-C Reduction on High-Intensity Statin Insights From JUPITER Trial

8. Lifestyle Modifications

9. Residual Risk

10. Improving Adherence With LLT

11. FH Illustrates the Importance of Documentation

12. Documenting Is Key to Achieving Lipid Therapeutic Goals

13. 2017 NLA Recommendations on the Use of PCSK9 Inhibitors

14. 2017 Updated ACC Consensus Document on Role of Non-Statin Therapies for LDL-C Lowering

15. Access to PCSK9 Inhibitors

16. Improving Access to PCSK9 Inhibitors

17. Concluding Remarks

18. Abbreviations